PolyBio

501(c)3 transforming how LongCovid, ME/CFS, Lyme+ and Alzheimer’s are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.

[PolyBio @polybioRF]

From Crisis to Cure: PolyBio is supporting top HIV researchers to pivot into the study and treatment of Long COVID. Watch the full video to learn how this collaboration is being maximized & driving forward innovative research: https://t.co/Fc6rLyNsab

[PolyBio @polybioRF]

See the full summit schedule and access the link to join on November 18-20 here: https://t.co/lZkwbblP24

[PolyBio @polybioRF]

PolyBio’s inaugural Convergence Summit 2026 is fast approaching! From November 18 to 20, presentations will address evolving research on the relationship between pathogens and chronic diseases such as Long COVID, chronic Lyme disease, MS, Alzheimer’s, and more.

The meeting will bring together leading researchers, clinicians, biotech innovators and public health experts to address the rapid need for IACI diagnostics and treatments to translate from the lab bench to hospital bedside.

[PolyBio @polybioRF]

Featured on @WCVB last night: PolyBio’s Scientific Director Dr. Amy Proal and PolyBio funder and collaborator Steve Pagliuca.

They highlighted the impact of Long COVID on patients’ quality of life—and how PolyBio’s research programs are rapidly validating tissue and biofluid-based diagnostic tests that will fill gaps in clinical care.

[PolyBio @polybioRF]

Attendees can also join directly at the American Academy of Arts & Science’s Zoom link from November 18-20 to hear all talks throughout the conference: https://t.co/6QyveDyljf

[PolyBio @polybioRF]

We’re pleased to announce the inaugural PolyBio Convergence Summit will take place this November 18 to 20.

Presentations will explore the latest advances in persistent infections and their emerging roles in conditions such as Long COVID, chronic Lyme disease, multiple sclerosis, Alzheimer’s, and aging. Discussions will focus on the practical challenges that must be addressed to translate these discoveries into validated diagnostics, clinical trials, and effective therapies.

Add the virtual schedule to your calendar here: https://t.co/rCydfm3p3L

[PolyBio @polybioRF]

The final summit day on November 20th will focus on treatment of acute infections to prevent chronic illness, innovative technologies in persistence research, and genetic/viral retroelements in chronic disease.

[PolyBio @polybioRF]

Eligibility criteria:
• You have a clinical diagnosis of chronic Lyme disease or post-treatment Lyme disease
• You have a clinical diagnosis of neuropathic pain
• You are 18 years or older
• You live in the United States and are able to attend virtual visits

If interested, please reach out to [email protected] to apply.

*Note that this is a randomized study with a 1:1 ratio of participants assigned to the treatment versus sham control.

https://t.co/XJ3DW5kqg3

[PolyBio @polybioRF]

Actively recruiting: Extended decentralized trial of a novel therapeutic device to reduce chronic pain in post-treatment Lyme disease

👉🏻Eligibility criteria below

The Sana Pain Reliever is a frequency-based therapeutic device that has been shown to reduce all-cause neuropathic pain. 1/

[PolyBio @polybioRF]

Additional markers including HRV and patient-reported changes to sleep quality will also be evaluated. Participants will be asked to complete several questionnaires and attend virtual visits throughout the trial period. 6/

[PolyBio @polybioRF]

5/ Watch Dr. Murakami’s full presentation from the PolyBio Spring 2026 Symposium here: https://t.co/1Tc0OZwtcj

[PolyBio @polybioRF]

At the Harvard/MIT Martinos Center, Dr. Mario Murakami and the VanElzakker lab are using ultrahigh-resolution 7T fMRI to understand how changes to cerebrospinal fluid (CSF) flow in people with Craniocervical Instability can produce a phenotype similar to that seen in ME/CFS and other neuroimmune conditions.

The brain relies on cerebrospinal fluid to carry out metabolic waste that builds up during normal physiological processes, acting as a “garbage disposal,” as explained by Murakami. Changes to healthy CSF flow may result in the buildup of these metabolites in the brain.

Said Murakami, “There is a compromised structure of CSF flow in CCI [patients] compared with healthy controls, which means that maybe this is part of the mechanisms which drive the symptoms—the brain fog, the pain, the fatigue, the autonomic dysfunction.”

[PolyBio @polybioRF]

4/ Early findings presented by Dr. Murakami providing evidence for these structural and functional differences in the IACI patient population may reflect a pre-existing vulnerability factor, or a consequence of pathology related to acute illness effects on cerebrospinal fluid pressure, infection, or inflammatory effects on the elasticity of the meninges or laxity of craniocervical structural ligaments.

[PolyBio @polybioRF]

3/ This study builds on growing evidence that a portion of patients with IACI, including Long COVID and ME/CFS, possess functional and structural brainstem abnormalities. The brainstem itself is additionally susceptible to CSF flow changes, and contains dorsal nuclei that control autonomic function, pain, sleep, and sickness behavior—which, if dysfunctional, could have implications for these functions.